DE60137362D1 - Nanopartikel bestehend aus einem arzneistoff und copolymeren von vinyl pyrrolidon und vinyl acetat als oberflächenstabilisatoren - Google Patents

Nanopartikel bestehend aus einem arzneistoff und copolymeren von vinyl pyrrolidon und vinyl acetat als oberflächenstabilisatoren

Info

Publication number
DE60137362D1
DE60137362D1 DE60137362T DE60137362T DE60137362D1 DE 60137362 D1 DE60137362 D1 DE 60137362D1 DE 60137362 T DE60137362 T DE 60137362T DE 60137362 T DE60137362 T DE 60137362T DE 60137362 D1 DE60137362 D1 DE 60137362D1
Authority
DE
Germany
Prior art keywords
copolymer
medicament
vinyl
vinyl acetate
surface stabilizers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60137362T
Other languages
German (de)
English (en)
Inventor
Henry William Bosch
Niels P Ryde
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perrigo Pharma International DAC
Original Assignee
Elan Pharma International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma International Ltd filed Critical Elan Pharma International Ltd
Application granted granted Critical
Publication of DE60137362D1 publication Critical patent/DE60137362D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
DE60137362T 2000-11-20 2001-11-16 Nanopartikel bestehend aus einem arzneistoff und copolymeren von vinyl pyrrolidon und vinyl acetat als oberflächenstabilisatoren Expired - Lifetime DE60137362D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71511700A 2000-11-20 2000-11-20
PCT/US2001/043111 WO2002094215A2 (en) 2000-11-20 2001-11-16 Nanoparticulate compositions comprising a drug and copolymers of vinyl pyrrolidone and vimyl acetate as surface stabilizers

Publications (1)

Publication Number Publication Date
DE60137362D1 true DE60137362D1 (de) 2009-02-26

Family

ID=24872726

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60137362T Expired - Lifetime DE60137362D1 (de) 2000-11-20 2001-11-16 Nanopartikel bestehend aus einem arzneistoff und copolymeren von vinyl pyrrolidon und vinyl acetat als oberflächenstabilisatoren

Country Status (8)

Country Link
EP (1) EP1341521B1 (cg-RX-API-DMAC10.html)
JP (2) JP4541647B2 (cg-RX-API-DMAC10.html)
AT (1) ATE419834T1 (cg-RX-API-DMAC10.html)
AU (1) AU2001297844A1 (cg-RX-API-DMAC10.html)
CA (1) CA2428785C (cg-RX-API-DMAC10.html)
DE (1) DE60137362D1 (cg-RX-API-DMAC10.html)
ES (1) ES2317874T3 (cg-RX-API-DMAC10.html)
WO (1) WO2002094215A2 (cg-RX-API-DMAC10.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
US8512727B2 (en) * 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
CA2858733C (en) * 2004-12-31 2017-12-19 Iceutica Pty Ltd Nanoparticle compositions and methods for synthesis thereof
CN101287451A (zh) * 2005-05-23 2008-10-15 依兰药物国际有限公司 包含血小板聚集抑制剂的毫微粒和控制释放组合物
WO2007046632A1 (en) * 2005-10-18 2007-04-26 Amorepacific Corporation Cationic polymer nanoparticles encapsulating an active ingredients, and the cosmetic composition containing the same
WO2008002485A2 (en) * 2006-06-23 2008-01-03 Alza Corporation Increased amorphous stability of poorly water soluble drugs by nanosizing
AU2016203251B2 (en) * 2006-06-30 2017-11-16 Iceutica Pty Ltd Methods for the Preparation of Biologically Active Compounds in Nanoparticle Form
JP5508003B2 (ja) * 2006-06-30 2014-05-28 アイスイティカ ピーティーワイ リミテッド ナノ粒子状の形態における生物学的に活性な化合物の調製のための方法
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
CA2759109A1 (en) 2009-04-24 2010-10-28 Iceutica Pty Ltd A solid dosage form of ciprofloxacin having small particle size and improved powder handling characteristics
NZ710384A (en) 2009-04-24 2017-03-31 Iceutica Pty Ltd A novel formulation of indomethacin
PE20140166A1 (es) * 2010-10-01 2014-02-17 Cipla Ltd Composicion farmaceutica que comprende deferasirox
JP2014129317A (ja) * 2012-02-23 2014-07-10 Canon Inc 光音響造影剤用色素含有ナノ粒子
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
WO2016134121A1 (en) 2015-02-20 2016-08-25 Cytec Industries Inc. Dialkyl sulfosuccinate compositions, method of making, and method of use
AU2017236423A1 (en) * 2016-03-24 2018-11-15 Locate Bio Limited Scaffolding material, methods and uses
GB201810925D0 (en) * 2018-07-03 2018-08-15 Blueberry Therapeutics Ltd Compositions and methods of treatment
ES2984690T3 (es) 2020-06-26 2024-10-30 Algiax Pharmaceuticals Gmbh Composición de nanopartículas
CR20230376A (es) * 2021-01-11 2023-12-12 Bayer Healthcare Llc Formulaciones de gel líquido concentradas que contienen sales de naproxeno

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2608988B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
GB9200607D0 (en) * 1992-01-13 1992-03-11 Ethical Pharma Ltd Pharmaceutical compositions containing nifedipine and process for the preparation thereof
FR2698560B1 (fr) * 1992-11-30 1995-02-03 Virbac Laboratoires Principes actifs pulvérulents stabilisés, compositions les contenant, leur procédé d'obtention et leurs applications.
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5326552A (en) * 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
ES2188883T3 (es) * 1996-07-08 2003-07-01 Ciba Sc Holding Ag Derivados de triazina como filtro uv en productos antisolares.
RU2186562C2 (ru) * 1996-08-22 2002-08-10 Ресеч Трайангл Фармасьютикалс Лтд. Композиции, представляющие собой микрочастицы веществ, нерастворимых в воде, и способ их изготовления
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
AU6283299A (en) * 1998-10-01 2000-04-17 Elan Pharma International Limited Controlled release nanoparticulate compositions
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate

Also Published As

Publication number Publication date
ES2317874T3 (es) 2009-05-01
WO2002094215A3 (en) 2003-05-01
CA2428785C (en) 2011-04-26
JP2004520443A (ja) 2004-07-08
EP1341521B1 (en) 2009-01-07
EP1341521A2 (en) 2003-09-10
WO2002094215A2 (en) 2002-11-28
JP2010111685A (ja) 2010-05-20
ATE419834T1 (de) 2009-01-15
CA2428785A1 (en) 2002-11-28
JP4541647B2 (ja) 2010-09-08
AU2001297844A1 (en) 2002-12-03

Similar Documents

Publication Publication Date Title
ATE419834T1 (de) Nanopartikel bestehend aus einem arzneistoff und copolymeren von vinyl pyrrolidon und vinyl acetat als oberflächenstabilisatoren
ATE464880T1 (de) Arzneistoffnanopartikel mit lysozym- oberflächenstabilisator
ATE381317T1 (de) Nanopartikuläre zusammensetzungen in form festen darreichungen
DK1429731T3 (da) Nanopartikelformuleringer indeholdende insulin
DK1553927T3 (da) Gel-stabiliserede, nanopartikulære aktivstof-sammensætninger
ATE431131T1 (de) Meloxican-formulierungen in nanoteilchenform
NZ573555A (en) Nanoparticulate posaconazole formulations
DE60222160D1 (de) Zusammensetzungen mit einer kombination aus eigenschaften sofortiger freisetzung und kontrollierter freisetzung
ATE234634T1 (de) Feste pharmazeutische formulierungen enthaltend eine physische mischung aus sulphoalkylethercyclodextrin und einem therapeutischen wirkstoff
WO2005049091A3 (en) Antibody-targeted nanoparticulate active agent delivery
ATE419835T1 (de) Nystatin-nanopartikelzusammensetzungen
EA200600877A1 (ru) Наночастицы для доставки лекарств
BRPI0519088A2 (pt) formulaÇÕes de tacrolimo nanoparticuladas
WO2007086914A3 (en) Nanoparticulate clopidogrel formulations
MX2009005727A (es) Nanoparticulas de entidad anfifilica.
ATE271383T1 (de) Pulverformulierung zur inhalation
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
ATE471144T1 (de) Intranasale verabreichung von schnell wirkendem insulin
TW200744677A (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
HRP20070198A2 (hr) Smjese estrogen-ciklodekstrin kompleksa
EA200701202A1 (ru) Препараты из наночастиц бензотиофена
EA200870060A1 (ru) Эмульсия бутилфталида для внутривенного введения и ее применение
CO5251419A1 (es) Composiciones nanoparticuladas de eplerenona
ES2183918T3 (es) Mezclas de resina de metacrilato.
ATE367165T1 (de) Xanthangummi enthaltende reepithelialisierende pharmazeutische zubereitungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition